Home  »  Finance   »  Meeting and exceeding analyst predictions: Immunic...

Meeting and exceeding analyst predictions: Immunic Inc. (IMUX)

Immunic Inc. (IMUX) is priced at $1.76 after the most recent trading session. At the very opening of the session, the stock price was $1.63 and reached a high price of $1.80, prior to closing the session it reached the value of $1.64. The stock touched a low price of $1.61.Recently in News on March 2, 2023, Immunic to Participate in Investor and Scientific Conferences in March. Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in March:. You can read further details here

Immunic Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $12.6387 on 04/05/22, with the lowest value was $1.1100 for the same time period, recorded on 12/19/22.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.


Immunic Inc. (IMUX) full year performance was -83.00%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Immunic Inc. shares are logging -86.07% during the 52-week period from high price, and 58.56% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.11 and $12.64.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 584699 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Immunic Inc. (IMUX) recorded performance in the market was 25.71%, having the revenues showcasing 41.94% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 89.90M, as it employees total of 66 workers.

Immunic Inc. (IMUX) in the eye of market guru’s

During the last month, 0 analysts gave the Immunic Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.6793, with a change in the price was noted -7.44. In a similar fashion, Immunic Inc. posted a movement of -80.87% for the period of last 100 days, recording 1,528,292 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for IMUX is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Immunic Inc. (IMUX): Stocks Technical analysis and Trends

Raw Stochastic average of Immunic Inc. in the period of last 50 days is set at 24.60%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 19.27%. In the last 20 days, the company’s Stochastic %K was 14.45% and its Stochastic %D was recorded 12.19%.

If we look into the earlier routines of Immunic Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 25.71%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -55.89%, alongside a downfall of -83.00% for the period of the last 12 months. The shares increased approximately by -7.85% in the 7-day charts and went up by -11.56% in the period of the last 30 days. Common stock shares were driven by 41.94% during last recorded quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts